# The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

> **NCT02658175** · PHASE3 · COMPLETED · sponsor: **Akcea Therapeutics** · enrollment: 68 (actual)

## Conditions studied

- Familial Chylomicronemia Syndrome
- Lipoprotein Lipase Deficiency
- Hyperlipoproteinemia Type 1

## Interventions

- **DRUG:** Volanesorsen

## Key facts

- **NCT ID:** NCT02658175
- **Lead sponsor:** Akcea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-23
- **Primary completion:** 2020-01-15
- **Final completion:** 2020-01-15
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658175, "The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02658175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*